Brought to you by 
Xenon licenses 1st Order's potassium channel modulator for epilepsy
11 Sep 2018
Executive Summary
Xenon Pharmaceuticals Inc. licensed exclusive worldwide rights to 1st Order Pharmaceuticals Inc.'s 1OP2198 compound, which Xenon will rename XEN1101 and develop for epilepsy.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Xenon licenses 1st Order's potassium channel modulator for epilepsy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice